Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Recruiting · NCT06243354 · Registry updated 2026-01-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation | Efficacy; Safety; Tolerability | Recruiting | Phase 1 / Phase 2 | 2026-01-29 | NCT06243354 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sichuan Huiyu Pharmaceutical Co., Ltd | 10 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fujian Provincial Cancer Hospital | Fuzhou | China | 6 |
| Hunan Provincial Cancer Hospital | Changsha | China | 1 |
| Shandong Provincial Cancer Hospital | Jinan | China | 1 |
| ShangHai Pulmonary Hospital | Shanghai | China | 11 |
| The First Hospital of China Medical University | Shenyang | China | 16 |
| West China Hospital of Sichuan University | Chengdu | China | 23 |